Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2Phase 3 2Phase 1 2Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 5Gastrointestinal 5Thoracic 4Breast 4Lymphoid 3Plasma cell 1Other solid neoplasm 1Head & Neck 1Genitourinary 1

Conditions

Multiple Myeloma 1Acute Kidney Injury 1

Interventions

Dexamethasone 11Lenalidomide 10Bortezomib 10Zoledronic Acid 8ixazomib 4daratumumab 4Thalidomide 4Melphalan 4Cyclophosphamide 4tocilizumab 3Prednisone 3pomalidomide 2carfilzomib 2Kyphoplasty 2Filgrastim 2Doxorubicin 2Calcium Dobesilate 2zanubrutinib 1talquetamab 1pegylated granulocyte colony-stimulating factor 1montelukast 1isatuximab 1ibrutinib 1fludarabine phosphate 1fludarabine 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1apixaban 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Drug Therapy × Plasma cell × Clear all
NCT05429515 2022-06-23

Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury

Peking Union Medical College Hospital

Phase 4 Not yet recruiting
50 enrolled
GenitourinaryPlasma cell

Multiple Myeloma, Acute Kidney Injury

Data powered by HemOnc (CC BY 4.0) Colophon âš¡